Significant Ownership of Sermonix Pharmaceuticals, Inc.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Sermonix Pharmaceuticals, Inc. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- David J. Portman - Chief Executive Officer
- Manager location
- Columbus, OH
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
CIK context first
Continue from Sermonix Pharmaceuticals, Inc.
Significant Ownership of Sermonix Pharmaceuticals, Inc.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| LONA | LeonaBio, Inc. | Common Stock | 25% | $11,264,709 | -$8,415,732 | 3,149,470 | -43% | Sermonix Pharmaceuticals, Inc. | 26 Oct 2026 |
Schedules 13D/G Reported by Sermonix Pharmaceuticals, Inc.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.